ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR).

Authors

Andrew Leonard Laccetti

Memorial Sloan Kettering Cancer Center, New York, NY

Andrew Leonard Laccetti , Matthew Raymond Smith , Howard I. Scher , Frank Verholen , Patrick Adorjan , Manjari Dissanayake , Xin Gao

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

A phase 2 randomized open-label study of oral darolutamide monotherapy vs. androgen deprivation therapy in men with hormone-naive prostate cancer (EORTC-GUCG 1532).

First Author: Bertrand F. Tombal

insert_chart_outlined

Poster

2018 Genitourinary Cancers Symposium

bookmark_border

Intergroup study EORTC-1532-gucg: A phase 2 randomized open-label study of oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in men with hormone naive prostate cancer (PCa).

First Author: Bertrand F. Tombal

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Enzalutamide, docetaxel and androgen deprivation (ENZADA trial) for metastatic castrate sensitive prostate cancer (mCSPC).

First Author: Earle F Burgess

insert_chart_outlined

Poster

2022 ASCO Genitourinary Cancers Symposium

bookmark_border

Evaluation of tumor genomic variants in Japanese patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide: Protocol of a phase 4 study (CUARTET).

First Author: Hirotsugu Uemura